15 October 2015 - IQWiG has found there is a survival advantage for nivolumab in treatment-naive patients with BRAF V600 negative tumours and that the effect varies by gender.

For more details, go to: https://www.iqwig.de/en/press/press-releases/press-releases/nivolumab-in-melanoma-added-benefit-in-certain-patients.6926.html [English]